Scope and claims analysis for US Patent 11,806,400: pre-filled IV bags for ibuprofen with defined NaOH:ibuprofen ratio and stability requirements
US 11,806,400 is a formulation-and-container patent focused on a stabilized aqueous ibuprofen solution packaged in a pre-filled IV bag, with tight physicochemical controls (NaOH:ibuprofen molar ratio, target pH, and clarity) and performance attributes (freeze-thaw stability, ambient storage stability, and accelerated degradation limits). The independent claim is directed to the pre-filled bag containing the defined composition, not to the act of making the solution. Dependent claims narrow container materials and sterilization/stability conditions. Method-of-use claims cover intravenous administration for pain and fever using the claimed pre-filled bag.
What patents protect pre-filled IV ibuprofen solutions with a defined NaOH:ibuprofen molar ratio?
Patent scope in one line
US 11,806,400 protects a pre-filled IV bag containing a clear, pH 7.4 aqueous ibuprofen solution where NaOH:ibuprofen molar ratio is ≥ 1.05:1, plus stability/sterility attributes, with downstream protection for IV treatment of pain and fever using that bag.
Core claim architecture
The claim set is built in three layers:
- Composition-in-pre-filled-bag (independent): water for injection, ibuprofen at a specified concentration in two embodiments (4 mg/mL in Claim 1; 800 mg ibuprofen in Claim 8), sodium chloride, sodium hydroxide, NaOH:ibuprofen molar ratio threshold, clear appearance, and pH 7.4.
- Container and process attributes (dependent): specific bag polymers (polypropylene, polyolefin, PVC) and preferred polypropylene; sterile filtration or terminal sterilization; and functional stability (clarity after freeze-thaw; clarity after 12 weeks at ambient; no detectable chemical degradation after 1 month at 40°C).
- Method-of-use: IV administration from the claimed pre-filled bag to treat pain (Claim 15) and fever (Claim 16).
What exactly are the independent claim boundaries in US 11,806,400?
Claim 1 (4 mg/mL embodiment) key limitations
Claim 1 requires all of the following, in combination, inside a pre-filled IV bag:
- Pre-filled bag for IV injection
- Stable pharmaceutical composition comprising:
- Water for injection
- Ibuprofen: 4 mg/mL
- Sodium chloride
- Sodium hydroxide
- NaOH:ibuprofen molar ratio ≥ 1.05:1
- Composition is clear
- pH is 7.4
Infringement analysis for Claim 1 turns on whether a competitor has:
- An IV-ready ibuprofen solution in a pre-filled bag with the same functional/physicochemical profile (clarity and pH),
- With sufficient base relative to ibuprofen (NaOH:ibuprofen molar ratio at or above 1.05:1),
- And within the 4 mg/mL concentration in the claimed embodiment.
Claim 8 (800 mg embodiment) key limitations
Claim 8 is the second concentration embodiment:
- Pre-filled bag for IV injection
- Stable composition comprising:
- Water for injection
- 800 mg ibuprofen (as recited)
- Sodium chloride
- Sodium hydroxide
- NaOH:ibuprofen molar ratio ≥ 1.05:1
- Clear and pH 7.4
Claim 8 is composition-in-container protection again, with a different quantitative ibuprofen “load” recited. The scope is therefore not only “pH and ratio,” but also “how much ibuprofen.”
Claim construction pressure points (practical)
Even without prosecution history, the claim text creates three high-pressure interpretive zones for enforcement and design-around:
-
“NaOH to ibuprofen molar ratio at least 1.05:1”
- This is a hard quantitative ceiling for infringement analysis.
- A competitor that uses a lower ratio may attempt to avoid, but will still need to maintain solubility and stability.
-
“clear” and “pH of 7.4”
- “Clear” is a functional appearance limitation.
- “pH of 7.4” can be attacked as overly strict if actual formulations vary around 7.4 within test tolerances, but the claim as written still forces the accused product into a pH band around that value.
-
“pre-filled bag for intravenous injection”
- If a competitor uses a vial/ampoule then transfers to an IV container at administration, they may argue they do not meet “pre-filled bag.” Conversely, if packaged as a single-use IV bag ready for infusion, they are likely closer to the claim.
What do the dependent claims add to the protected product profile?
Bag material limitation (Claims 2–3; 9–10)
- Claim 2: bag made of polypropylene, polyolefin, or polyvinylchloride.
- Claim 3: bag is polypropylene.
- Claim 9: same material group for the 800 mg embodiment.
- Claim 10: bag is polypropylene.
Enforcement implication: if a competitor uses a different polymer (e.g., EVA multilayer, co-extruded structures, multilayer laminates not captured by these categories), they may avoid the narrower dependent claims but still risk the broader independent claim if independent claims do not require a specific polymer. Here, the independent claims as provided do not specify bag material, so polymers may not reduce independent-claim risk unless the competitor can argue the product is not the same “pre-filled bag” type or not “for intravenous injection.”
Sterilization limitation (Claims 4; 11)
- Composition is sterile filtered or terminally sterilized.
This adds another gate for infringement. A product manufactured under aseptic non-sterilization conditions (if any) could try to argue it does not meet this limitation. Practically, many sterile products fit this anyway.
Freeze-thaw clarity limitation (Claims 5; 12)
- Composition “remains clear when exposed to at least one freeze-thaw cycle.”
This is a functional stability criterion. For design-around, a competitor must show the accused solution does not remain clear after such exposure, which may be difficult if the formulation is intended to be robust.
Ambient storage clarity (Claims 6; 13)
- “clear when stored for at least 12 weeks at ambient temperature.”
This sets a minimum stability duration and appearance requirement.
Accelerated chemical stability (Claims 7; 14)
- “no detectable chemical degradation after incubation for one month at 40° C.”
This is the strongest objective performance limitation in the dependent claim set. It narrows the protected scope to solutions that do not degrade under accelerated conditions. For infringement, “no detectable” implies an analytical detection threshold tied to method. In practice, it becomes a laboratory fight: what assay, what LOQ, and what species count as “chemical degradation.”
How broadly does the patent reach: formulation-only, or also use?
Method-of-use protection (Claims 15–16)
- Claim 15: method of treating pain by administering the pharmaceutical composition from the pre-filled bag of Claim 1 IV to a patient.
- Claim 16: method of treating fever by administering the pharmaceutical composition from the pre-filled bag of Claim 1 IV.
These are classic downstream method-of-use claims. They do not require the defendant to manufacture the bag, only to practice the claimed method. The infringement risk is highest where the accused product is the same pre-filled bag formulation and clinicians administer it for the covered indications.
Coverage note: Claims 15–16 reference “pre-filled bag according to claim 1,” meaning the pain/fever methods specifically tie to the 4 mg/mL embodiment as written. The 800 mg embodiment (Claim 8) is not expressly linked to the method-of-use clauses you provided.
Timeline: when does exclusivity end in the US patent estate?
The user request does not include the filing date, priority date, issuance date, Patent Term Adjustment, or any terminal disclaimer. Those facts determine patent term expiration and any adjusted “in-force through” date.
Because those inputs are not provided, a complete exclusivity and expiration timeline cannot be produced from the claim text alone.
Patent landscape build: what other IP layers typically exist around this kind of ibuprofen IV formulation?
Even without pulling external records, the claim set you provided implies three adjacent IP clusters likely in the same family or related filings:
1) Formulation patents around alkaline solubilization and stability
To keep ibuprofen soluble at physiological-range pH, developers typically adjust:
- base (NaOH or equivalent),
- ionic strength (sodium chloride),
- possibly co-solvents, surfactants, or buffer systems,
- and packaging/container interactions.
US 11,806,400 already locks key elements:
- NaOH:ibuprofen ratio ≥ 1.05:1
- pH 7.4
- clarity retention
- accelerated stability
Any continuation or related patents would likely attempt to capture:
- other ibuprofen concentrations and fill volumes,
- other pH targets or ranges,
- alternate salts or counterions,
- stability claims with additional time/temperature conditions,
- or additional container permeability/scalability controls.
2) Container and pre-filled administration system patents
The dependent claims on polymer types suggest separate container-related IP may exist:
- bag material selection,
- oxygen/moisture barrier layers,
- extractables/leachables controls,
- compatibility with NaOH-containing solutions,
- and stability after handling (freeze-thaw).
3) Sterilization method and process robustness patents
The “sterile filtered or terminally sterilized” limitation can intersect with:
- filtration membrane compatibility,
- aseptic processing vs terminal sterilization validation,
- and claims tied to reduced degradation after specific sterilization cycles.
How strong is the patent for enforcement: claim specificity vs design-around latitude?
Strength factors
- Quantitative threshold (NaOH:ibuprofen molar ratio ≥ 1.05:1).
- Explicit pH target (7.4).
- Explicit appearance requirement (“clear”).
- Multi-axis stability (freeze-thaw clarity, 12-week ambient clarity, 1-month 40°C no detectable degradation).
- Specific container format (pre-filled IV bag).
- Sterility processing condition.
This combination can be difficult for generics/biosimilars-like entrants to replicate without measurement-driven alignment.
Design-around pressure points
A competitor’s strongest routes to non-infringement are typically:
- Adjust base level below the molar ratio threshold (but must still solubilize and stay clear at pH 7.4).
- Move pH away from “pH of 7.4” (again while maintaining stability and clarity).
- Use a different dosage form/packaging system not meeting “pre-filled bag” (e.g., concentrate in vial with reconstitution).
- Fail the functional performance claims (not remaining clear after freeze-thaw, not remaining clear after 12 weeks ambient, or showing detectable degradation under 40°C/1 month).
- Avoid the 4 mg/mL embodiment linkage for the method-of-use. If they sell only a different concentration and do not administer the Claim 1 formulation, Claims 15–16 may not map.
What would a non-clinical infringement test look like for a competitor product?
For products potentially accused of infringing US 11,806,400, technical comparisons generally focus on:
- Composition assays
- ibuprofen concentration (4 mg/mL vs other)
- sodium chloride presence and levels (claim requires it, but no numeric values were provided in your recitation)
- NaOH level and resulting NaOH:ibuprofen molar ratio
- pH measurement
- confirm actual pH target around 7.4 at relevant conditions
- Appearance
- “clear” after defined stress steps
- Stability protocols
- freeze-thaw cycle(s) used by the patentee
- 12-week ambient storage
- 40°C for one month and “no detectable chemical degradation” with a defined assay/LOQ
The patent’s strongest leverage is the multi-stage stability gate, particularly the “no detectable chemical degradation” clause.
Key takeaways
- US 11,806,400 is a pre-filled IV bag formulation patent for ibuprofen with a defined alkaline solubilization regime (NaOH:ibuprofen molar ratio ≥ 1.05:1) and a tight target pH (7.4) plus clarity and stability requirements.
- The claims cover specific ibuprofen loading embodiments (4 mg/mL and 800 mg as recited) and extend to sterility and stability performance through dependent claims.
- Method-of-use coverage is limited to IV administration for pain and fever using the Claim 1 (4 mg/mL) pre-filled bag formulation.
- Enforcement strength comes from stacked quantitative and functional limitations; main design-around levers are base ratio, pH, clarity/stability outcomes, and potentially packaging format.
FAQs
1) Can a competitor avoid US 11,806,400 by lowering the NaOH:ibuprofen molar ratio below 1.05:1?
A lower ratio is the most direct claim carve-out for the composition limitations, but infringement can still occur if other aspects still match and the product’s measured ratio exceeds the threshold in practice.
2) Does US 11,806,400 require a specific buffer system beyond sodium chloride and sodium hydroxide?
The recited claims only require water for injection, ibuprofen, sodium chloride, and sodium hydroxide, with pH and stability constraints.
3) If a product is clear and pH is near 7.4, can it still infringe if it degrades during the 40°C/1-month test?
If the product shows detectable chemical degradation under the claimed condition and with the relevant detection method, it may fail dependent claim requirements, though independent-claim risk depends on whether those specific functional limitations are part of the asserted claim.
4) Do the method-of-use claims apply to the 800 mg ibuprofen embodiment?
As provided, Claims 15–16 reference the pre-filled bag according to Claim 1, tying coverage to the 4 mg/mL embodiment.
5) Could using a different IV container material avoid the patent?
Dependent claims narrow container materials; however, independent claims as recited do not require a specific bag polymer, so container-only changes may not eliminate risk unless they also affect “pre-filled bag for intravenous injection” characterization or other limitations.
References
No external sources were cited because no bibliographic or patent-record details (publication number, assignee, priority, filing/issuance dates, family members, or prosecution history) were provided beyond the claim text you included.
